TCRX vs. LRN

Last updated Jun 4, 2026

TCRX (TScan Therapeutics, Inc.) and LRN (Stride, Inc.) are both stocks. TCRX operates in Biotechnology (Healthcare), while LRN operates in Education & Training Services (Consumer Defensive). Over the past 3 years, TCRX returned -29.80%/yr vs 33.48%/yr for LRN. At a 0.08 correlation, their price movements are largely independent.

Performance

TCRX vs. LRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TScan Therapeutics, Inc. (TCRX) and Stride, Inc. (LRN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TCRX achieves a -2.80% return, which is significantly lower than LRN's 53.44% return.

TCRX

• 1D: -0.82%
• 1M: -20.33%
• YTD: -2.80%
• 6M: -4.71%
• 1Y: -44.46%
• 3Y*: -29.80%
• 5Y*: —
• 10Y*: —

LRN

• 1D: 1.76%
• 1M: 7.99%
• YTD: 53.44%
• 6M: 62.77%
• 1Y: -30.11%
• 3Y*: 33.48%
• 5Y*: 28.19%
• 10Y*: 23.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TCRX vs. LRN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
TCRX TScan Therapeutics, Inc.	-2.80%	-67.11%	-47.86%	276.13%	-65.56%	-57.14%
LRN Stride, Inc.	53.44%	-37.53%	75.05%	89.80%	-6.15%	5.37%

Correlation

The correlation between TCRX and LRN is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.10
Correlation (3Y) Calculated over the trailing 3-year period	0.07
Correlation (All Time) Calculated using the full available price history since Jul 19, 2021	0.08

Fundamentals

Market Cap TCRX : $126.28M LRN : $4.74B
EPS TCRX : -$0.96 LRN : $9.68
PS Ratio TCRX : 15.48 LRN : 1.90
PB Ratio TCRX : 1.30 LRN : 2.89
Total Revenue (TTM) TCRX : $8.15M LRN : $2.54B
Gross Profit (TTM) TCRX : $6.66M LRN : $972.24M
EBITDA (TTM) TCRX : -$129.32M LRN : $424.60M

Return for Risk

TCRX vs. LRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TCRX

TCRX Risk / Return Rank: 20
TCRX Sharpe Ratio Rank: 18
TCRX Sortino Ratio Rank: 23
TCRX Omega Ratio Rank: 23
TCRX Calmar Ratio Rank: 16
TCRX Martin Ratio Rank: 21

LRN

LRN Risk / Return Rank: 25
LRN Sharpe Ratio Rank: 21
LRN Sortino Ratio Rank: 27
LRN Omega Ratio Rank: 26
LRN Calmar Ratio Rank: 25
LRN Martin Ratio Rank: 27

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TCRX vs. LRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for TScan Therapeutics, Inc. (TCRX) and Stride, Inc. (LRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TCRX	LRN	Difference
Sharpe ratio: Return per unit of total volatility	-0.52	-0.45	-0.07
Sortino ratio: Return per unit of downside risk	-0.35	-0.08	-0.27
Omega ratio: Gain probability vs. loss probability	0.96	0.98	-0.02
Calmar ratio: Return relative to maximum drawdown	-0.69	-0.47	-0.22
Martin ratio: Return relative to average drawdown	-1.01	-0.73	-0.28
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TCRX vs. LRN - Sharpe Ratio Comparison

The current TCRX Sharpe Ratio is -0.52, which is comparable to the LRN Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of TCRX and LRN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TCRX	LRN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.52	-0.45	-0.07
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.55	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.48	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.39	0.15	-0.55

Drawdowns

TCRX vs. LRN - Drawdown Comparison

The maximum TCRX drawdown since its inception was -93.36%, which is greater than LRN's maximum drawdown of -81.41%. Use the drawdown chart below to compare losses from any high point for TCRX and LRN.

Drawdown Indicators

	TCRX	LRN	Difference
Max Drawdown Largest peak-to-trough decline	-93.36%	-81.41%	-11.95%
Max Drawdown (1Y) Largest decline over 1 year	-64.46%	-64.07%	-0.39%
Max Drawdown (3Y) Largest decline over 3 years	-90.58%	-64.07%	-26.51%
Max Drawdown (5Y) Largest decline over 5 years	—	-64.07%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-64.07%	—
Current Drawdown Current decline from peak	-92.79%	-41.33%	-51.46%
Average Drawdown Average peak-to-trough decline	-71.82%	-36.27%	-35.55%
Ulcer Index Depth and duration of drawdowns from previous peaks	44.25%	41.53%	+2.72%

Volatility

TCRX vs. LRN - Volatility Comparison

TScan Therapeutics, Inc. (TCRX) has a higher volatility of 17.58% compared to Stride, Inc. (LRN) at 7.85%. This indicates that TCRX's price experiences larger fluctuations and is considered to be riskier than LRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TCRX	LRN	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.58%	7.85%	+9.73%
Volatility (6M) Calculated over the trailing 6-month period	50.67%	23.81%	+26.86%
Volatility (1Y) Calculated over the trailing 1-year period	87.56%	67.31%	+20.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	98.20%	51.38%	+46.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	98.20%	49.23%	+48.97%

Dividends

TCRX vs. LRN - Dividend Comparison

Neither TCRX nor LRN has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both TCRX and LRN in my portfolio?

TCRX and LRN have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TCRX or LRN?

TCRX has higher volatility (17.58%) compared to LRN (7.85%). In terms of maximum drawdown, TCRX dropped -93.36% vs LRN's -81.41%.

Which has better risk-adjusted returns?

LRN currently has the higher Sharpe Ratio (-0.45 vs -0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.